Matisse Capital

Position in SPRY — ARS Pharmaceuticals, Inc.

CIK 1668256 PORTLAND, OR

Position in SPRY

as of Jun 30, 2026 · filed Aug 12, 2026 Compact

Position Value

$526,265

-$13,583 QoQ

Shares Held

65,701

-2.3% QoQ

Ownership

0.066%

of shares outstanding

% of Portfolio

0.25%

of 13F equity value

Holder Rank

#72

of 208 holders

Holding Since

Mar 2025

6 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Matisse Capital holds $8,732,734 across 4 Biotechnology names. SPRY ranks #2 (6.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S	28,107	$7,496,699
2	SPRY	ARS Pharmaceuticals, Inc. This page	65,701	$526,265
3	RYTM	Rhythm Pharmaceuticals, Inc.	4,000	$444,120
4	WVE	Wave Life Sciences, Inc.	45,723	$265,650

6 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$526,265	65,701	-2.3%	Shares	Sole	2026-08-12
2026-03-31	$539,848	67,229	+21.0%	Shares	Sole	2026-05-08
2025-12-31	$647,285	55,561	-3.9%	Shares	Sole	2026-01-29
2025-09-30	$580,799	57,791	+1.9%	Shares	Sole	2025-10-29
2025-06-30	$989,659	56,714	+1.8%	Shares	Sole	2025-07-23
2025-03-31	$700,882	55,714	—	Shares	Sole	2025-04-24
No filing history on record for this holder in this stock.